becotatug vedotin

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
becotatug vedotin

GtoPdb Ligand ID: 14392

Synonyms: MEIYOUHENG® (China) | MRG-003 | MRG003

becotatug vedotin is an approved drug

Compound class: Antibody

Comment: Becotatug vedotin (MRG003) is a fully human anti-EGFR antibody-drug conjugate [5]. The payload is the synthetic antimitotic agent/tubulin polymerization inhibitor monomethyl auristatin E (MMAE). Becotatug vedotin was designed for potential antitumour activity.

References
1. Blair HA. (2026) Becotatug Vedotin: First Approval. Drugs, 86 (4): 573-579. [PMID:41787195]
2. Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P et al.. (2026) Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial. Med, 7 (4): 101029. [PMID:41720100]
3. Jing R, Zhi X, Shao L. (2026) Approvals by the China NMPA in 2025. Nat Rev Drug Discov, 25 (3): 164-165. [PMID:41688808]
4. Qiu MZ, Zhang Y, Guo Y, Guo W, Nian W, Liao W, Xu Z, Zhang W, Zhao HY, Wei X et al.. (2022) Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol, 8 (7): 1042-1046. [PMID:35511148]
5. Yu J, Fang T, Yun C, Liu X, Cai X. (2022) Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci, 9: 847835. [PMID:35295841]

References

1. Blair HA. (2026)
Becotatug Vedotin: First Approval.
Drugs, 86 (4): 573-579. [PMID:41787195]

2. Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P et al.. (2026)
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial.
Med, 7 (4): 101029. [PMID:41720100]

3. Jing R, Zhi X, Shao L. (2026)
Approvals by the China NMPA in 2025.
Nat Rev Drug Discov, 25 (3): 164-165. [PMID:41688808]

4. Qiu MZ, Zhang Y, Guo Y, Guo W, Nian W, Liao W, Xu Z, Zhang W, Zhao HY, Wei X et al.. (2022)
Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.
JAMA Oncol, 8 (7): 1042-1046. [PMID:35511148]

5. Yu J, Fang T, Yun C, Liu X, Cai X. (2022)
Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.
Front Mol Biosci, 9: 847835. [PMID:35295841]